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Development of an effective preventive or therapeutic vaccine against HIV-1 is an important goal in the fight against AIDS.
Effective virus clearance and inhibition of spread to target organs depends principally on the cellular immune response.
Therefore, a vaccine against HIV-1 should elicit virus-specific cytotoxic lymphocyte (CTL) responses to eliminate the virus
during the cell-associated stages of its life cycle. The vaccine should also be capable of inducing immunity at the mucosal
surfaces, the primary route of transmission. Recombinant Bacille Calmette–Gue´rin (BCG) expressing viral proteins offers an
excellent candidate vaccine in view of its safety and ability to persist intracellularly, resulting in the induction of long-lasting
immunity and stimulation of the cellular immune response. BCG can be administered orally to induce HIV-specific immunity
at the mucosal surfaces. The immunogenicity of four recombinant BCG constructs expressing simian immunodeficiency virus
(SIV) Gag, Pol, Env, and Nef proteins was tested in rhesus macaques. A single simultaneous inoculation of all four
recombinants elicited SIV-specific IgA and IgG antibody, and cellular immune responses, including CTL and helper T cell
proliferation. Our results demonstrate that BCG recombinant vectors can induce concomitant humoral and cellular immune
responses to the major proteins of SIV. © 2000 Academic PressINTRODUCTION
An ideal vaccine should be safe, stable, inexpensive,
and able to elicit immune responses appropriate for the
clearance or inhibition of the pathogen in question. Cel-
lular rather than humoral immune responses are more
effective in clearing cell-associated virus infection
(Rouse et al., 1988). Conversely, many extracellular par-
asites are most effectively removed by the humoral com-
ponent of the immune system (Ziegelbauer, 1993). Since
HIV-1 and simian immunodeficiency virus (SIV) life cycles
have both intracellular and extracellular stages and are
primarily transmitted through mucosal surfaces, an ef-
fective vaccine should be capable of inducing systemic
and mucosal immunity including both cellular and hu-
moral immune responses.
The live attenuated strain of Mycobacterium bovis,
Bacille Calmette–Gue´rin (BCG), has a long history of
successful vaccine application in both human and non-
human primates. It has been proven safe in various
vaccine trials and, indeed, many countries, with the ex-
ception of the United States, exercise routine vaccination
with BCG for protection against tuberculosis (Guerin,
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941991; Sedaghatian and Kardouni, 1993). BCG has also
been successfully used to nonspecifically stimulate cell
immunity as a treatment for superficial bladder cancer
and skin melanomas (D’Ancona et al., 1991; Lamm, 1995;
Mack and Frick, 1995; Melekos et al., 1993; Thanos et al.,
1995). Since its initial use as a vaccine against tubercu-
losis in 1921, more than two billion individuals have been
vaccinated with a very low incidence of reported com-
plications (Lotte et al., 1984, 1988; Luelmo, 1982; UNICEF,
1985). Intradermal and oral administration of BCG to
newborns as well as to adults have provided long-lasting
immunity due to BCG’s ability to persist and replicate in
macrophages for several decades (Appelberg, 1992;
Dannenberg, 1994; Fine et al., 1994; Pithie et al., 1992).
Moreover, BCG is well suited for application in develop-
ing countries, principally for its inexpensive production
cost and heat stability.
Since HIV-1 and SIV infections are primarily cell-asso-
ciated, it is improbable that a humoral response alone
can prevent viral spread. Previous HIV-1 and SIV vac-
cines geared toward the induction of virus neutralizing
antibodies have had limited success (Berman et al.,
1988; Hu et al., 1987). In murine influenza and cytomeg-
alovirus systems, cytotoxic T lymphocytes (CTL) have
been capable of eliminating or stopping the spread of the
virus (Lukacher et al., 1984; Quinnan et al., 1982; Yap et
al., 1978). Other studies have reported CTL inhibition of
HIV and SIV replication in vitro (Kannagi et al., 1988;
95PRIMATE IMMUNE RESPONSE TO rBCG EXPRESSING SIV PROTEINSTsubota et al., 1989; Walker et al., 1987), and have shown
that virus-specific CTL can delay disease onset (Koup et
al., 1994; Miller et al., 1990; Safrit et al., 1994). Because of
its innate adjuvant properties and the potential to stim-
ulate CTL against HIV and SIV infections, BCG provides
an ideal vaccine vehicle that should also induce CTL at
mucosal sites (Dimov et al., 1992; Gheorghiu, 1994; Munk
et al., 1994; Stover et al., 1994).
Advances in recombinant DNA technology allow ex-
pression of foreign proteins in BCG (Aldovini and Young,
1991; Barletta et al., 1990; Murray et al., 1992; Ranes et
al., 1990; Stover et al., 1991). When BCG was used for the
expression of Leishmania surface protein gp63, effective
immunity was generated against challenge with infec-
tious Leishmania (Cohn, 1997). In addition, several other
groups have engineered HIV and SIV proteins to BCG
and detected cellular and/or humoral responses in var-
ious animal systems (Aldovini and Young, 1991; Fuerst et
al., 1992; Kameoka et al., 1994; Winter et al., 1991; Yasu-
tomi et al., 1993). However, a recombinant BCG express-
ing a SIV gag single epitope failed to protect macaques
against intravenous challenge with cell-free SIV (Yasu-
tomi et al., 1995).
We have studied the immune response to SIV and
HIV-1 and have focused in the development and testing
of AIDS vaccine candidates (Torres et al., 1993; Anderson
et al., 1994; Meyer et al., 1998; Meyer and Torres et al.,
1999). In this study, the immunogenicity of recombinant
BCG (rBCG) expressing several SIV proteins was tested
using the SIV rhesus macaque animal model. For the first
time, rBCG constructs containing the four major open
reading frames of the SIV genome (gag, pol, env, and nef)
were combined in a single inoculum and given to rhesus
macaques intravenously (iv). The results demonstrate
the induction of SIV-specific systemic IgA and IgG anti-
body and cellular immune responses including CTLs and
helper T cell proliferation.
RESULTS
Cloning and expression of rBCG-Gag, Pol, Env, and
Nef. The entire coding sequences of SIV gag, pol, and
nef were separately subcloned into a BCG–Escherichia
coli shuttle vector that replicates extrachromosomally.
The SIV genes were placed under the regulatory control
of the HSP70 promoter that was constitutively active. The
env gene was subcloned similarly to the other genes
except the potentially toxic, hydrophobic signal peptide
and transmembrane segment were removed. We there-
fore expected to see a truncated version of Env in the
Western blots. Initial screening for protein expression in
E. coli was done using Western blot and polyclonal and
monoclonal antibodies specific for the respective pro-
teins. The vectors validated for expression of the appro-
priate proteins were electroporated into BCG and colo-
nies were screened for SIV protein expression. Figure 1shows the expression of SIVmac Env, Nef, Gag, and Pol
detected by macaque polyclonal antibodies. The molec-
ular weight of nef protein correlates with the respective
proteins in the SIVmac239 virus lysate and that of env,
with the size predicted from the gene truncated at the 59
and 39 ends. Bands were also obtained for recombinant
BCG expressing HIV Gag and Pol (lanes 5 and 6). No
reactivity with proteins from mock transfected BCG was
detected (lane 2). Lane 7 shows a band pattern demon-
strating specific binding of SIVmac proteins by the poly-
clonal antibodies.
SIV-specific lysis of rVV-labeled B-LCL targets. Periph-
eral blood mononuclear cells (PBMCs) from six inocu-
lated rhesus macaques were tested for their ability to
lyse autologous B-LCL targets expressing SIV proteins.
Prior to the assay, PBMCs were nonspecifically stimu-
lated with Con A for 3 days and subsequently expanded
in IL-2 medium for an additional 3 days. As seen in Fig.
2, specific CTL activity was detected against one or all
the SIVmac proteins in the immunized rhesus macaques.
No CTL was detected in the nonimmunized controls
(data not shown). One macaque was sacrificed a month
after rBCG inoculation and the remaining five animals
were kept until the end of the study. By 30–34 days
following rBCG inoculation, specific lytic activity to
SIVmac Pol and Env proteins but not SIVmac Gag was
detected in Monkey 1 (Fig. 2). The other five macaques
(Monkeys 2–6) also had CTLs specific for more than one
SIVmac protein present at several time points. CTL re-
sponses to Gag, Pol, and Env proteins were demon-
strated for Monkey 2 at 41, 158, and 180 days after rBCG
inoculation. For Monkey 3, CTLs specific for Pol and Env
proteins were detected at 25 days and to all three pro-
FIG. 1. SIV protein expression by recombinant BCG. Western blot
analysis of rBCG expressing SIV Env, Nef, Gag, and Pol proteins. The
samples were prepared as described under Materials and Methods.
Specific SIV proteins were detected by 1:800 dilution of polyclonal sera
from an SIV-infected rhesus macaque. Antigens: Lane 1, molecular
weight markers; Lane 2, wild-type BCG; Lane 3, rBCG-env; Lane 4,
rBCG-nef; Lane 5, rBCG-gag; Lane 6, rBCG-pol; and Lane 7, SIVmac.teins tested at day 137. CTLs to envelope were present in
Monkey 4 at both 25 and 159 days postinoculation. CTL
ercenta
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detectable as early as 25 days and remained high at 159
days in Monkeys 5 and 6 (Fig. 2). Overall, consistent CTL
responses to SIVmac Gag, Pol, and Env in PBMCs of five
of the six vaccinated monkeys were demonstrated in the
study.
SIV-specific IgA and IgG response. The PBMCs of the
rBCG-inoculated rhesus macaques were tested at differ-
ent times postinoculation and varying levels of SIV-spe-
cific IgA and IgG secretion were detected in all the
immunized monkeys (Fig. 3). One macaque (Monkey 7)
was an infected control. IgA and IgG levels specific for
both recombinant envelope glycoprotein (gp130) and
FIG. 2. CTL response induced by recombinant BCG. PBMCs from rB
rVV expressing SIVmac251 Gag, Pol, or Env proteins. PBMCs were assa
infected with wild-type vaccinia were used as negative controls. The p
Spontaneous release was less than 20%.whole SIV antigen were secreted by PBMCs harvested
from all the animals tested (Monkeys 2–6). A panel ofuninfected macaques was used to establish the baseline
control values (,0.2 OD units at 405 nm). In addition,
these assays were also performed using PBMCs from
the study animals before immunization to confirm base-
line values. Data presented in Fig. 3 show that these
responses increase over time after immunization for the
duration of the testing period. With the exception of IgG
levels to whole SIV, both IgA and IgG levels to gp130 in
the immunized animals were higher than those found in
the infected control (Monkey 7).
Additional immunological assessment. Further analy-
sis of the immune response induced by the recombinant
BCG expressing SIV gag, pol, env, and nef revealed
culated rhesus macaques specifically lyse B-LCL targets labeled with
several dates postinoculation as indicated on the x axis. B-LCL targets
ge specific release shown is after subtraction of wild-type rVV values.CG-ino
yed atdetectable antibody levels in some animals. Four out of
the six animals were positive for antibodies to purified
S
s
n
1
97PRIMATE IMMUNE RESPONSE TO rBCG EXPRESSING SIV PROTEINSprotein derivative by ELISA and all the animals were
positive for antibodies specific for BCG by Western blot.
ELISA and Western blot analysis showed that three ma-
caques produced detectable antibodies to our SIVmac
nef expressed in E. coli. Furthermore, detectable titers of
IV neutralizing antibodies were observed in four of the
ix macaques.
DISCUSSION
With advances in rDNA technology, BCG can be engi-
eered to express foreign proteins (Aldovini and Young,
991; Stover et al., 1991). Other desirable characteristics,
such as its long safety record in humans, stability, low
cost, and particularly its innate ability to stimulate CTL
production, make rBCG expressing HIV-1 proteins an
FIG. 3. Humoral response following recombinant BCG inoculation.
IgA/IgG secreted by PBMCs from rBCG-inoculated rhesus macaques.
PBMCs were assayed by cell ELISA at several dates postinoculation as
indicated on the x axis. An SIV-infected rhesus macaque was used as
a positive control (Monkey 7). Error bars indicate variation among
individual wells for each macaque. All assays were done at least in
triplicate. The upper baseline value of 0.2 OD at 405 nm established
with a panel of uninfected macaques was subtracted from each data
point.ideal vaccine candidate against AIDS. Information re-
garding the dose, route, immunogenicity, safety, and ef-ficacy of BCG immunization against tuberculosis in rhe-
sus macaques, combined with the availability of the SIV
rhesus macaque animal model of simian AIDS, prompted
us to evaluate the potential of rBCG as a vaccine against
human AIDS (Barclay et al., 1973; Chaparas et al., 1975;
Good, 1968). Preexisting immunization with BCG has not
been shown to interfere with the use of rBCG as a
vaccine vector nor BCG used as an immune adjuvant in
the treatment of certain carcinomas.
SIV infection of rhesus macaques is an excellent
model for AIDS in humans. SIV and HIV-1 have similar
genetic organization and cell tropism for the CD4 recep-
tor and induce a similar AIDS-like disease in macaques
and humans, respectively. The main difference is a short-
ened disease course for SIV, (6 months–2 years in ma-
caques) in comparison to HIV-1 (6–10 years in humans)
(Kangnoff, 1978; Kuller et al., 1990; Letvin et al., 1985;
Letvin and King, 1990).
We have tested the immunogenicity of rBCG express-
ing SIV Gag, Pol, Env, and Nef proteins in rhesus ma-
caques by administering all four recombinants in a sin-
gle inoculation. The dose was chosen from an early
study evaluating the safety and efficacy of inoculated
native BCG as a vaccine against simian tuberculosis
(Good, 1968). More recent studies with rBCG expressing
either SIV Gag or Nef proteins inoculated intradermally
were successful in eliciting SIV-specific CTL (Yasutomi et
al., 1993). The objective of the present study was to
determine whether simultaneous inoculation of all four
rBCGs would elicit immune responses to all four SIV
proteins (Gag, Pol, Env, and Nef), and, if so, to identify the
pattern and duration of the responses. Recombinant
BCG expressing Nef was specifically included since Nef
is one of the earliest proteins expressed during natural
HIV-1/SIV infection and is important in maintaining a high
virus load in vivo (Ameisen et al., 1989; Koenig et al.,
1990). Thus, the induction of CTL immune responses
against Nef may be important in controlling virus spread.
Unfortunately, because the recombinant vaccinia ex-
pressing SIV Nef was unavailable to us, we were unable
to determine whether CTLs against Nef were present. It
is highly unlikely, however, that CTL responses would be
generated against only Gag, Pol, Env, and not Nef, par-
ticularly in light of previous studies that show Nef is
immunogenic (Bourgault et al., 1992; Culmann et al.,
1991; Koenig et al., 1990; Lamhamedi-Cherradi et al.,
1992; Venet et al., 1992; Yasutomi et al., 1993). In addition,
we performed ELISA and Western blot assays that dem-
onstrated a humoral response against E. coli-expressed
Nef in three of the monkeys (data not shown). Purified
recombinant Nef expressed in E. coli was prepared by
our lab for use in these experiments. Therefore, rBCG
was able to induce a Nef-specific humoral immune re-
sponse in at least 50% of the animals.Outbred populations with extensive MHC polymor-
phism will develop CTLs against one or more but not
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98 LEUNG ET AL.necessarily all HIV-1 or SIV proteins, and the recognition
pattern can change over time (Phillips et al., 1991; Walker
t al., 1987). Therefore, vaccine strategies against AIDS
hould generate immune responses against multiple vi-
al components as well as account for escape mutants
hat frequently arise in the course of HIV-1 and SIV
nfection (Phillips et al., 1991). Our data highlight differ-
nces in the kinetics of CTL responses directed against
ajor proteins of SIV when expressed by a live vector in
ivo.
Interestingly, we found that early after inoculation of
he macaques with the four recombinant BCGs (approx-
mately 4 weeks), the dominant CTL responses were
irected against Pol and Env (in 4/6 monkeys) as op-
osed to Gag (in 1/6 monkeys). This is somewhat sur-
rising given that the Gag-specific CTL response has
een characterized as the dominant CTL epitope after
IV-infection of rhesus macaques (Egan et al., 1999). A
previous study examined CTL responses over time
against SIVmac Gag, Env, and Nef after infection of
rhesus macaques with SIVmac (Yasutomi et al., 1993).
The earliest CTL response was directed against Env
(within 1 week) and later against Gag and Nef (at 4
weeks postinfection), confirming our results regarding an
early Env-specific CTL response. One possible explana-
tion for a slower Gag-specific response in our study is
that the Gag-expressing rBCG replicated at a slower rate
in vivo relative to the other rBCGs, thus delaying induc-
ion of a Gag-specific CTL response. We find this un-
ikely, however, as one of our monkeys mounted a very
otent Gag-specific CTL response and minimal Pol- and
nv-specific responses early after inoculation (Monkey
). Thus, we believe that inoculation of macaques with
ive rBCGs expressing multiple SIV antigens, or infection
ith live SIVmac, leads to early anti-SIV responses di-
ected against Pol and Env and later against Gag.
The importance of the kinetics of CTL responses di-
ected against the various proteins of SIV and HIV in
elation to protection from infection of disease is not yet
lear. One study found that, among recently serocon-
erted HIV-infected individuals, the earliest CTL re-
ponses are directed against Gag and Env, with little
eactivity against HIV-1 Pol (Legrand et al., 1997). In
contrast, another longitudinal and cross-sectional study
examined CTL responses in relation to the vertical trans-
mission of HIV-1 (Jin et al., 1998). Limiting dilution anal-
ysis was used to quantitate CTL frequencies against
HIV-1 Gag, Pol, Env, and Nef in 15 women who transmit-
ted disease and in 16 women who did not transfer dis-
ease. CTL frequencies directed against Pol and Nef were
higher during the pregnancies of nontransmitters com-
pared to those women transmitting virus. Thus, in animal
models of HIV infection and among HIV-infected individ-
uals, the kinetics of CTL responses against the major
viral proteins differ from one another. Moreover, the viraltargets of early CTL responses may impact the clinical
course of HIV-1 infection.
Since HIV-1 is generally transmitted sexually via mu-
cosal surfaces, a vaccine should ideally generate muco-
sal immunity. A major component of mucosal immune
responses involves IgA-secreting plasma cells at muco-
sal sites. Interestingly, detection of a systemic antigen-
specific IgA response may be indicative of mucosal im-
munity (Forrest, 1992). All the inoculated rhesus ma-
caques in this study demonstrated systemic SIV-specific
IgA responses which varied over time, generally peaking
between 160 and 190 days after inoculation. In fact,
virus-specific IgA responses dominated IgG responses
at late (160–190 days) time points in inoculated ma-
caques. In marked contrast, virus-specific IgG responses
were dominant in an SIV-infected macaque (Monkey 7). It
is possible that the extended duration of the IgA antibody
response demonstrated here is due to the persistence
and replication of the rBCG at both mucosal and nonmu-
cosal sites, thus providing continuous antigenic stimula-
tion. The intravenous route was chosen as an aggressive
approach to testing the immunogenicity of the rBCG
constructs and is not meant to be suggested as a vac-
cination route. Studies comparing the immunogenicity of
the four rBCGs administered orally, intragastrically, and
intradermally are in progress.
HIV-1 and SIV exist as cell-associated and cell-free
viruses; therefore, an effective vaccine must generate
both cellular and humoral immunity. Modifications in
expression of foreign antigens, such as exportation to or
away from cell surfaces, may lead to an increase in
virus-specific antibody expression. Indeed, significant in-
creases in humoral responses can occur when foreign
proteins are directed to the membrane surface or se-
creted into the extracellular medium, together with cyto-
kines (O’Donnell et al., 1994; Stover et al., 1993). We have
also developed a combination approach with SIV-spe-
cific peptides and rBCG to elicit both cellular and hu-
moral immunity to SIV/HIV-1 (Appelberg, 1992). Oral ad-
ministration of rBCG may elicit a stronger local IgA re-
sponse due to lymphocyte homing mechanisms and the
common mucosal pathway (McDermott and Bienen-
stock, 1979). Recent studies have demonstrated the in-
duction of neutralizing antibodies and T cell proliferation
in small animals by rBCG expressing SIV proteins (Lim et
al., 1997).
HIV-2 has a similar genomic organization and anti-
genic profile as that of SIVmac. Therefore, it is logical to
assume that an effective vaccine against SIV in rhesus
macaques will also protect against HIV-2 in humans. We
intend to develop this vaccine for use against HIV-2
infection and disease progression in West Africa. In
addition, rBCG as a vaccine vector has recently acquired
renewed importance due to the worldwide reemergence
of human tuberculosis (Cohn, 1997).
With the SIV/rhesus macaque animal model of simian
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individual rBCG vectors expressing SIV Gag, Pol, Env,
and Nef proteins can induce SIV-specific CTL directed to
more than one protein. Within 1 month of inoculation,
CTL responses were directed against Pol and Env, and
later against Gag. Furthermore, SIV-specific IgA antibod-
ies were also elicited systemically. The long record of
safety of BCG use in humans, the innate adjuvant prop-
erties, and the role of CTL in controlling HIV-1 replication
and spread suggest that rBCG may yet prove an excel-
lent vaccine vector against AIDS.
MATERIALS AND METHODS
Animals. Healthy adult rhesus macaques (Macaca mu-
latta) were selected and housed at the California Re-
gional Primate Research Center at the University of Cal-
ifornia, Davis, in accordance with the guidelines estab-
lished by the American Association for the Accreditation
of Laboratory Animal Care (Assurance No. A3433-01). All
animals were screened for retroviruses including STLV,
SRV, and SIV. Collection of blood samples for PBMCs,
serum, and plasma was obtained by venipuncture after
sedation with ketamine hydrochloride (10–40 mg/kg).
Construction of rBCG vectors. The construction of the
expression vectors pY6013 and pYUB12 has been previ-
ously described (Aldovini and Young, 1991; Snapper et
al., 1988). Briefly, pY6013 contains the mycobacterial
hsp70 promoter and coding sequence; pYUB12 contains
the origins of replication for both E. coli (P15A) and
mycobacterium, as well as the Tn903-derived aph gene
to confer kanamycin resistance. Construction of the
rBCG involved a two-step process wherein the gene of
interest was first inserted into pY6013 so as to place it in
frame and under the regulatory control of the hsp70
promoter. The specific DNA insert was obtained by poly-
merase chain reaction (PCR). The PCR was performed in
a Perkin–Elmer Cetus DNA thermocycler (Perkin–Elmer
Cetus, Norwalk, CT). All DNA fragments were generated
using SIVmac239-specific primers which were designed
to introduce a NcoI site overlapping the translation initi-
ation codon at the 59 end, and a XbaI site immediately
following the translation stop codon. The reaction mix-
ture contained a total volume of 100 ml, consisting of 100
ng template, 40 pmol of each primer, 2 U TaqI polymer-
ase (Perkin–Elmer Cetus), 0.2 mM of each dNTP (Phar-
macia, Piscataway, NJ), 103 reaction buffer (500 mM KCl,
100 mM Tris–HCl at pH 8.3, 25 mM MgCl2, 0.1% gelatin),
and 50 ml mineral oil. The DNA was amplified for 30
ycles with temperatures for denaturing at 94°C, anneal-
ng at 56°C, and extension at 72°C. From pY6013, a
.8-kb DNA fragment was removed by a NcoI/XbaI diges-
ion and the PCR-generated DNA gag, pol, env, or nef
fragment was inserted (the translation initiation codon
for the hsp70 coding sequence also overlaps a NcoI
site). The gene of interest and the hsp70 promoter werethen excised with an EcoRI/XbaI digest (the EcoRI site
was blunt-ended with T4 DNA polymerase) and ligated
into the EcoRV/XbaI sites of the pYUB12 E. coli–myco-
bacterial shuttle vector.
DNA fragments were generated using SIVmac251 or
SIVmac239 primers designed to introduce a NcoI site at
the junction of promoter and open reading frame, and a
KpnI or XbaI site immediately following the translation
stop codon. The following oligonucleotides were used in
the synthesis of the different genes: gag (59 to 39):
GCGCGAGAAACGCCGTCTTGTCA (SIVmac251), AGG-
TACCCTACTGGTCTCCTCCAAAGAGAGA (SIVmac251
lus KpnI site); pol (59 to 39): AACCCGGGAGCCCCAA-
AAGACAGAGATG (SIVmac251 plus SmaI site), ATC-
CGGGCTATGCCACCTCTCTAGCCTCTCC (SIVmac251
lus SmaI site); env (59 to 39): CAGTCTCCATGGGTGTAC-
AGCTTGG (SIVmac239/251 plus NcoI), CCACCTCTA-
ATTACCTCTTCACATCTGTGG (SIVmac239/251 plus
baI); nef (59 to 39): CTACAATCCCGGGGGAGCTATTTC-
ATGAG (SIVmac239/251 plus SmaI site), GTCCCTTCTA-
ATCAGCGAGTTTCC (SIVmac239 plus XbaI site).
Gag and Pol primers were synthesized according to
he sequence reported previously that relates to
IVmac251 (Accession No. M19499) with some differ-
nces (Franchini et al., 1987). The PCR reaction was
arried out with TaqI polymerase according to the man-
facturer’s protocol (Perkin–Elmer Cetus). Gag, pol, env,
nd nef gene fragments were cloned in plasmid pY6013
containing the HSP70 promoter (Aldovini and Young,
1991). For the gag gene, pY6013 was cut with NcoI, filled
in with Klenow, and digested with KpnI. The plasmid
vector without HSP70 coding sequence was selected
and ligated with a purified gag PCR product that was
filled in with Klenow and then cut with KpnI. A recombi-
nant plasmid containing the gag gene that recreates the
NcoI site at the junction of the HSP70 promoter and the
gag open reading frame was selected. For the pol gene,
pY6013 was cut with NcoI and KpnI and filled in with
Klenow. Plasmid vector without HSP70 coding sequence
was selected and ligated with a pol PCR product di-
gested with SmaI. A recombinant plasmid containing the
pol gene in the correct orientation was selected. DNA
fragments covering the env and nef sequences replaced
the HSP70 coding region in pY6013 as NcoI–XbaI and
SmaI–XbaI fragments, respectively.
The four recombinant plasmids containing SIV genes
downstream of the HSP70 promoter were digested with
EcoRI, filled in with Klenow, and partially (gag and pol) or
completely (env and nef) digested with XbaI. Fragments
containing the gag, pol, env, and nef genes driven by the
HSP70 promoter were isolated from the digested plas-
mids and inserted in the backbone of pYUB12, purified
after digestion with EcoRV and XbaI.
The entire coding sequences of SIVmac239 gag, pol,
and nef were inserted into pYUB12. However, it was
necessary to truncate the SIV env coding sequence to
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100 LEUNG ET AL.remove certain hydrophobic regions since foreign genes
overexpressing hydrophobic regions can be toxic to pro-
karyotic cells. We therefore designed primers based on
exclusion of the amino-terminal signal peptide and the
hydrophobic transmembrane segment at the carboxyl
terminal. The resulting PCR-derived DNA fragment was
then inserted into pYUB12.
The DNA constructs were transformed into E. coli
DH5a and colonies were screened by restriction enzyme
nalysis. Positive colonies were expanded and the re-
ombinant DNA constructs were purified by cesium chlo-
ide banding. Monoclonal antibodies specific for Gag,
ol, Nef, and Env were used to confirm the expression of
hese antigens in E. coli. The rDNA constructs were
ubsequently electroporated into wild-type BCG and
creened for appropriate protein expression by Western
lot.
Growth of rBCG. The Pasteur strain of BCG (TMC 1011,
merican Type Culture Collection (ATCC) No. 35734) was
btained from the ATCC and grown in Middlebrook 7H9
roth (Difco, Detroit, MI) supplemented to a final concen-
ration of 10% albumin–dextrose complement (Difco),
.05% Tween 80 (Sigma, St. Louis, MO), and 0.2% glycerol
Fisher, Springfield, NJ). The supplemented medium was
eferred to as complete MB7H9. Kanamycin (Sigma) was
sed as a selectable marker for the rBCG (20 mg/ml).
Bacterial cultures were grown at 37°C until they reached
mid-log phase, and were then harvested for electropo-
ration. Briefly, BCG was washed and resuspended to
one-tenth their original volume and 0.4 ml was aliquoted
into 0.4-cm electroporation cuvettes (Bio-Rad, Richmond,
CA). Recombinant BCG DNA constructs were added to
the cells (1 mg DNA) and the cuvettes were placed in a
io-Rad Gene Pulser with an attached pulse controller
Bio-Rad). The BCG constructs were electroporated at 25
mF and 2.5 kV. After approximately 4 weeks, individual
colonies were selected and expanded in 25 ml of com-
plete MB7H9 plus kanamycin and grown at 37°C until
mid-log phase. rBCG cell lysates were obtained by son-
ication with a Microson microtip sonicator (Misonix,
Farmingdale, NJ) using two 10-s pulses. The rBCG ly-
sates (200 ml) were added to 50 ml of 53 Laemmli’s
buffer (Laemmli, 1970) and boiled at 100°C for 5 min. The
cellular debris was pelleted by centrifugation for 3 min at
10,000 rpm (Savant Instruments, Farmingdale, NY) and
20 ml of each lysate was assayed by Western blot anal-
sis for appropriate protein expression.
Western blot analysis. Lysates from each of the rBCG
olonies were screened by Western blotting for SIV pro-
ein expression. One milliliter of rBCG at mid-log phase
as centrifuged in a microcentrifuge for 1 min at 10,000
pm and resuspended in 0.5 ml of sterile PBS. Samples
ere sonicated with a Misonix microtip sonicator using
wo 10-s pulses, then 23 Laemmli’s buffer (Laemmli,
970) was added and samples were denatured by boiling
t 100°C for 5 min. Proteins were resolved in a discon-
pinuous acrylamide gel system consisting of a 10% re-
olving gel and 5% stacking gel. Proteins were trans-
erred to a nitrocellulose membrane (Amersham, Arling-
on Heights, IL) and blocked with Blotto (5% nonfat milk
n PBS in 0.1% Tween 20) for 1 h at room temperature.
fter the membrane was washed three times with PBS
ontaining 0.1% Tween 20, polyclonal sera from an
IVmac251-infected rhesus monkey was added (1:800)
nd incubated at room temperature for 1 h with gentle
gitation. The membrane was washed again and a sec-
ndary goat-anti-human antibody conjugated to alkaline
hosphatase (Fisher Biotech) was added (1:800). The
embrane was again washed and 15 ml of p-nitro blue
etrazolium 5-bromo-4-chloro-3-indolyl phosphate sub-
trate was added.
Immunization. To prepare for inoculations, 500 ml of
ach rBCG was grown in Fernbach flasks and harvested
t mid-log phase. The cells were tested for lack of bac-
erial contamination and for viability by staining with both
ram and Kinyoun’s cold acid-fast stains (Fisher). To
btain approximately 1 3 108 CFU of each rBCG, a
pecific volume of each supernatant was harvested
ased on previous growth curves correlating OD and
FU/ml. The actual concentrations were obtained by
itration and compared with the estimated values. Briefly,
he rBCGs were titrated by plating dilutions and counting
he colonies on Middlebrook 7H10 agar supplemented
ith 0.5% glycerol, 0.05% Tween 80, and 20 mg/ml kana-
ycin. The individual rBCGs were subsequently com-
ined and another aliquot was set aside for titration. The
ombined rBCGs were concentrated in a 5-ml volume in
terile saline for inoculation into rhesus macaques.
Rhesus macaques were inoculated iv with a high dose
f rBCG (5–7 3 108 CFU/rhesus) concentrated in a 5-ml
volume. According to the guidelines of the study, one
macaque was sacrificed after 1 month and the tissues
were stored for further analysis.
Cytotoxic T lymphocyte assays. Effector cells: Blood
was obtained by venipuncture and lymphocytes were
collected by Ficoll–Hypaque density centrifugation (Or-
ganon Teknika, Durham, NC). The PBMCs were placed in
culture at a concentration of 1 3 106 cells/ml and stim-
lated for 3 days in complete medium [RPMI 1640 sup-
lemented with 10% fetal calf serum (Gemini Bioproducts
nc., Calabasas, CA)], 2 mM L-glutamine (Sigma), and 50
mg/ml gentamicin sulfate (Irvine Scientific, Santa Ana,
CA) containing 5 mg/ml Con A (Sigma). After the 3-day
ncubation, the PBMCs were washed once with com-
lete medium, and stimulated an additional 3 days in
omplete medium containing 40 U/ml of recombinant
uman IL-2 (Chiron Corp., Emeryville, CA). At the end of
he 6-day stimulation period, the effectors were centri-
uged, washed once with complete medium, and resus-
7ended to 1 3 10 cells/ml. Twofold serial dilutions were
performed and 0.1 ml of 1 3 107 cells/ml through 1.25 3
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101PRIMATE IMMUNE RESPONSE TO rBCG EXPRESSING SIV PROTEINS106 cells/ml dilutions were added to each of four wells in
triplicate.
Target cells: Autologous B lymphocyte cell lines (B-
LCL) were obtained by transformation of macaque PBMC
with Herpes papio and subsequently stored in liquid
nitrogen (Miller et al., 1990). To generate SIV-specific
targets, autologous B-LCL were infected with recombi-
nant vaccinia (rVV) that expressed either SIVmac251
Gag, Pol, or Env as previously described by Letvin (Miller
et al., 1990; Yasutomi et al., 1996). The recombinant
vaccinia virus expressing SIV Nef was not available.
Cells were infected at a multiplicity of infection of 5
PFU/cell and incubated at 37°C for 16 h. They were then
washed twice and cell concentration and viability were
determined by trypan blue exclusion (Sigma). The target
cells were labeled by incubation with 0.2 mCi of
Na2
51CrO4 (Amersham) for 1 h at 37°C. The targets were
washed three times with complete medium. To obtain
effector:target cell ratios of 100:1, 50:1, 25:1, and 12.5:1, 0.1
ml of a 1 3 105 cells/ml target cell concentration was
added to effector cells in the appropriate wells. Effector
and target cells were incubated for 5 h at 37°C in a 5%
CO2 atmosphere. The cells were then pelleted by cen-
trifugation for 10 min at 200 g. Supernatant (100 ml) was
ollected and counted in a 1260 multigamma counter
LKB Wallac, Finland). The total 51Cr content was ob-
tained by addition of 0.1 ml 5% Nonidet P-40 (Sigma) to
wells containing target cells only. Spontaneous release
values obtained from wells containing labeled targets
and medium only were less than 20%. Specific release
was calculated as [(experimental release 2 spontane-
ous release)/(100% release 2 spontaneous release)] 3
100. The calculated specific release values represent the
lysis of target cells infected with rVV expressing SIVmac
Gag, Pol, or Env minus the specific lysis of the target
cells infected with the wild-type vaccinia strain.
IgA/IgG assay. As a marker for potential mucosal and
systemic immune responses, SIV-specific IgA and IgG
secreted from PBMC were assayed using a modified
protocol (Forrest, 1988, 1992). It was previously shown
that antigen-specific IgA secreted by human PBMCs 7
days after mucosal immunization was more indicative of
mucosal immune responses than IgA from serum, saliva,
or intestinal wash (Forrest, 1992). Therefore, to determine
if a single inoculation of rBCG expressing SIV Gag, Pol,
Env, and Nef would be able to elicit SIV-specific IgA
responses, a modification of this IgA ELISA was per-
formed as described below.
Fresh rhesus PBMCs were stimulated on ELISA plates
containing either bound inactivated SIV or recombinant
gp130 as antigens. Briefly, wells of a 96-well plate were
coated with either 200 ng/well of whole-inactivated
SIVmac239 or 800 ng/well of SIVmac251 rgp130. The
plate was then blocked with Blotto (10% nonfat milk in
PBS containing 0.5% bovine serum albumin and 0.05%
Tween 20). PBMCs were added at a concentration of 5 3105 cells/well in 0.1 ml and incubated for 16 h at 37°C in
a 5% CO2 incubator. The plates were washed three times
ith ELISA wash buffer (PBS containing 0.05% Tween 20
nd 0.02% sodium azide). To detect secreted IgA or IgG
ntibodies, rabbit anti-monkey IgA or IgG (Nordic Immu-
ology, Tilburg, The Netherlands) was added at a dilution
f 1:1000 and incubated for 4 h at 37°C. The plates were
gain washed and the tertiary antibody, goat anti-rabbit
onjugated to alkaline phosphatase (Fisher Biotech),
as added at a dilution of 1:1000 and incubated for 1 h
t 37°C. After the plates were washed, 0.1 ml of a 1
g/ml solution of p-nitrophenyl phosphate in 10% dieth-
nolamine buffer (Sigma) was added and the absor-
ance was read at 405 nm on an EIA autoreader model
L310. Wells were blanked with values from antigen-
oated wells incubated with only the alkaline phospha-
ase conjugated antibody. We also determined that com-
arison of values obtained from experimental cells incu-
ated with antigen versus experimental cells incubated
ithout antigen was an accurate indicator of antigen-
pecific antibody secretion. This is significant particu-
arly because the assay requires the use of fresh
BMCs, which makes comparison to preimmunization
alues difficult due to possible interassay variation.
herefore, the assay was also performed as previously
escribed with the addition of Blotto-coated wells (no
ntigen) incubated with the PBMCs. In addition, baseline
ontrol values were established with a panel of unin-
ected macaques and were less than 0.2 OD units at
05 nm.
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